Abstract: An EV charger includes a modular housing system that includes a first housing and a second housing. The first housing is adapted to enclose electrical circuitry that connects power source inputs from a power source input cable to EV charging outputs of an EV charging output cable. The first housing includes a first port and a second port. The first housing receives the input cable through the first port and sends the output cable through the second port. The second housing includes multiple ports. The second housing receives the output cable through one of its ports. The second housing further includes an EV charging socket or a tethered EV charger connector for charging an EV. In one embodiment, the second housing can be separated from the first housing using a conduit. In another embodiment, the second housing can be directly connected to the first housing.

Abstract: An EV charger connector holder includes a housing with a base and cover and at least one removable socket plug. The housing includes a first opening and a second opening. The base includes a base plate, a first base plug-holding structure, and a second base plug-holding structure. The cover includes a first cover plug-holding structure and a second cover plug-holding structure. When the base and the cover are attached, the first base plug-holding structure and the first cover plug-holding structure form a first housing port at the first opening and the second base plug-holding structure and the second cover plug-holding structure form a second housing port at the second opening. The removable socket plug includes an outside structure adapted for fixation to the first housing port or the second housing port and an inside structure adapted for receiving and locking to a first type of electrical connector.

Abstract: A biologically active complex comprising a polypeptide having the sequence of a naturally occurring protein or a variant thereof, wherein said polypeptide is at least partially unfolded as compared to the said naturally occurring protein for example as a result of a modification of at least one cysteine residue; or a peptide of up to 50 amino acids; and a fatty acid or lipid or a salt thereof, for use in prophylactic treatment of cancers, in particular of the gastrointestinal tract. Compositions that may comprise the complex and have use as nutraceuticals are obtainable from milk or milk fractions and form a further aspect of the invention. Methods of treatment in particular for the prevention of cancer form a further aspect of the invention.

Abstract: A biologically active complex comprising a polypeptide having the sequence of a naturally occurring protein or a variant thereof, wherein said polypeptide is at least partially unfolded as compared to the said naturally occurring protein for example as a result of a modification of at least one cysteine residue; or a peptide of up to 50 amino acids; and a fatty acid or lipid or a salt thereof, for use in prophylactic treatment of cancers, in particular of the gastrointestinal tract. Compositions that may comprise the complex and have use as nutraceuticals are obtainable from milk or milk fractions and form a further aspect of the invention. Methods of treatment in particular for the prevention of cancer form a further aspect of the invention.

Abstract: An in-vehicle monitoring device includes both forward facing and rear facing cameras. The in-vehicle monitoring device can detect occurrence of one or more triggering events and flag portions of captured videos. The flagged video portions may be transferred to other devices.

Abstract: A biologically active complex comprising a polypeptide having the sequence of a naturally occurring protein or a variant thereof, wherein said polypeptide is at least partially unfolded as compared to the said naturally occurring protein for example as a result of a modification of at least one cysteine residue; or a peptide of up to 50 amino acids; and a fatty acid or lipid or a salt thereof, for use in prophylactic treatment of cancers, in particular of the gastrointestinal tract. Compositions that may comprise the complex and have use as nutraceuticals are obtainable from milk or milk fractions and form a further aspect of the invention. Methods of treatment in particular for the prevention of cancer form a further aspect of the invention.

Abstract: The invention provides a method for preparing a biologically active complex, said method comprising dissolving a mixture of a polypeptide element, such as alphalactalbumin or fragments thereof, in powder form and oleic acid or a pharmaceutically acceptable salt thereof also in solid form, in an aqueous solvent comprising a mixture of at least two and preferably three salts, wherein the method is carried out at moderate temperatures. The preparation does not require extensive heating and so is simple and efficient to carry out.

Abstract: An in-vehicle monitoring device includes both forward facing and rear facing cameras. The in-vehicle monitoring device can detect occurrence of one or more triggering events and flag portions of captured videos. The flagged video portions may be transferred to other devices.

Abstract: The invention provides a method for preparing a biologically active complex, said method comprising dissolving a mixture of a polypeptide element, such as alphalactalbumin or fragments thereof, in powder form and oleic acid or a pharmaceutically acceptable salt thereof also in solid form, in an aqueous solvent comprising a mixture of at least two and preferably three salts, wherein the method is carried out at moderate temperatures. The preparation does not require extensive heating and so is simple and efficient to carry out.

Abstract: A biologically active complex comprising a peptide of up to 50 amino acids in length which comprises an alpha-helical domain of a protein which has membrane perturbing activity or a variant thereof which lacks cysteine residues, and oleic acid or a salt thereof, provided the protein is other than alpha-lactalbumin. Complexes of this type are useful in therapy, in particular cancer therapy.

Abstract: The present disclosure relates to compositions and methods for increasing the stability of an engineered protein by halogenating at least one amino acid residue of the protein to form a stabilizing hydrogen bond-enhanced halogen bond (HeX-B).

Abstract: A biologically active complex comprising a polypeptide having the sequence of a naturally occurring protein or a variant thereof, wherein said polypeptide is at least partially unfolded as compared to the said naturally occurring protein for example as a result of a modification of at least one cysteine residue; or a peptide of up to 50 amino acids; and a fatty acid or lipid or a salt thereof, for use in prophylactic treatment of cancers, in particular of the gastrointestinal tract. Compositions that may comprise the complex and have use as nutraceuticals are obtainable from milk or milk fractions and form a further aspect of the invention. Methods of treatment in particular for the prevention of cancer form a further aspect of the invention.

Abstract: A biologically active complex comprising either a polypeptide having the sequence of a variant of a naturally occurring protein, wherein said polypeptide is at least partially unfolded as compared to the said naturally occurring protein; or a peptide of up to 50 amino acids, for instance a fragment of the naturally occurring protein or a variant thereof; and a pharmaceutically acceptable salt of a fatty acid or lipid. The complexes of the invention demonstrate a novel mode of action, which gives rise to opportunities for the development of further active agents and screening methods.

Abstract: A biologically active complex comprising either a polypeptide having the sequence of a variant of a naturally occurring protein, wherein said polypeptide is at least partially unfolded as compared to the said naturally occurring protein; or a peptide of up to 50 amino acids, for instance a fragment of the naturally occurring protein or a variant thereof; and a pharmaceutically acceptable salt of a fatty acid or lipid. The complexes of the invention demonstrate a novel mode of action, which gives rise to opportunities for the development of further active agents and screening methods.

Abstract: A biologically active complex comprising a polypeptide having the sequence of a naturally occurring protein or a variant thereof, wherein said polypeptide is at least partially unfolded as compared to the said naturally occurring protein for example as a result of a modification of at least one cysteine residue; or a peptide of up to 50 amino acids; and a fatty acid or lipid or a salt thereof, for use in prophylactic treatment of cancers, in particular of the gastrointestinal tract. Compositions that may comprise the complex and have use as nutraceuticals are obtainable from milk or milk fractions and form a further aspect of the invention. Methods of treatment in particular for the prevention of cancer form a further aspect of the invention.

Abstract: A biologically active complex comprising either a polypeptide having the sequence of a variant of a naturally occurring protein, wherein said polypeptide is at least partially unfolded as compared to the said naturally occurring protein; or a peptide of up to 50 amino acids, for instance a fragment of the naturally occurring protein or a variant thereof; and a pharmaceutically acceptable salt of a fatty acid or lipid. The complexes of the invention demonstrate a novel mode of action, that gives rise to opportunities for the development of further active agents and screening methods.

Abstract: A biologically active complex comprising either a polypeptide having the sequence of a variant of a naturally occurring protein, wherein said polypeptide is at least partially unfolded as compared to the said naturally occurring protein; or a peptide of up to 50 amino acids, for instance a fragment of the naturally occurring protein or a variant thereof; and a pharmaceutically acceptable salt of a fatty acid or lipid. The complexes of the invention demonstrate a novel mode of action, that gives rise to opportunities for the development of further active agents and screening methods.

Abstract: A collet is provided for picking up a die mounted on an adhesive surface. A flat platform at an end of the collet is configured to hold a planar surface of the die during pick-up of the die and a flange protruding from one side of the platform is operative to push against a side of the die which is substantially perpendicular to the planar surface of the die during a die pick-up process.

Abstract: A sequence online analytical processing (S-OLAP) system 50 for analysing an event database (41) storing events (12), the system (50) comprising: an S-OLAP engine (53) to compute an S-cuboid (49) for a query on the event database (41); a sequence query engine (54) to form part of the S-cuboid (49) by performing the steps of: selection, clustering, sequence formation and sequence grouping; a cuboid repository (52) to store computed S-cuboids (49) and to be searched by the S-OLAP engine (53) for an S-cuboid query to determine whether an S-cuboid has previously been computed; and a sequence cache (56) to cache constructed sequence groups.

Abstract: A chassis for telecommunication gear including horizontal circuit boards includes an enclosure forming a front-accessible circuit board slot for receiving horizontal circuit boards. The circuit board slot has first connectors for receiving mating second connectors on the circuit boards, and multiple circuit board guides for guiding and securing horizontal circuit boards inserted into the slot. Adjacent pairs of the guides are spaced to receive circuit boards of predetermined widths, and at least one of the guides is removable so that it can be re-positioned within the slot for changing the spacing between adjacent pairs of the guides to receive circuit boards of different widths. The circuit boards may be telecommunication line cards.